A Phase III Double-Blind, Randomized, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterized by PTEN deficiency
Clinical Trial Type: Prostate
CC-94676- (Celgene)
CC-94676- (Celgene) Description: A Phase 1, Multi-Center, Open-Label, Dose Finding Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of CC-94676 In Subjects With Metastatic Castration-Resistant Prostate Cancer Target Patient Population: Prostate Cancer Study Design: Drug is given orally daily.